We identify novel drugs that can inhibit TRF1 in both lung cancer and glioblastoma cells, including inhibitors of some of the most deregulated pathways in cancer, namely, the Ras pathway (ERKi and MEKi), the cell cycle‐related CDK inhibitor, the inhibitor of the chaperone HSP90, two chemotherapeutic agents (gemcitabine and docetaxel), and RTK and mTOR inhibitors. Here, MTOR is linked to lung carcinoma.